Mouse Monoclonal MSH2 antibody [1B3=3A2B8C] (STJ98252)

$379.00

Reactivity: Human, Monkey
Applications: WB, IHC, IF, ELISA
Conjugation: Unconjugated
Supplier: St John’s Laboratory Ltd.

Clear
-$50 as credit for submitting review for primary antibody
Shipping notice:
Product will be delivered in 6 to 8 Business Days

Mouse Monoclonal MSH2 antibody [1B3=3A2B8C] (STJ98252)

Supplier: St John’s Laboratory Ltd.

Recommended applications: WB, IHC, IF, ELISA

Recommended dilution: WB 1:500-1:2000; IHC 1:200-1:1000; IF 1:200-1:1000; ELISA 1:10000

Recommended protocols: check protocols

Image descriptions:

Click or hover above images to see image description for MSH2 Monoclonal Antibody.

Alternative names:

Check alternative names for the antibody

Expand

MSH2 antibody,|BAT26 antibody|COCA 1 antibody|COCA1 antibody|DNA mismatch repair protein Msh2 antibody|FCC 1 antibody|FCC1 antibody|hMSH2 antibody|HNPCC 1 antibody|HNPCC antibody|HNPCC1 antibody|LCFS2 antibody|MSH 2 antibody|Msh2 antibody|MSH2_HUMAN antibody|MutS homolog 2 antibody|MutS homolog 2 colon cancer nonpolyposis type 1 antibody|MutS protein homolog 2 antibody|Anti-MSH2 antibody [3A2B8C] (ab52266)
SCBT cat No: sc-56163|sc-376384|sc-515356|sc-365052|sc-376501|sc-22771|sc-494|

 

Name

MSH2 Monoclonal Antibody

Catalogue No.

STJ98252

Reactivity

Human, Monkey

Specificity

MSH2 Monoclonal Antibody detects endogenous levels of MSH2 protein.

Immunogen

Purified recombinant fragment of human MSH2 expressed in E Coli

Host

Mouse

Applications

WB, IHC, IF, ELISA

Recommended dilution

WB 1:500-1:2000; IHC 1:200-1:1000; IF 1:200-1:1000; ELISA 1:10000

Clonality

Monoclonal

Conjugation

Unconjugated

Isotype

IgG1

Formulation

MSH2 Antibody was tube-contained. Ascitic fluid containing 0.03% sodium azide.

Concentration

1 mg/ml

Purification

MSH2 Antibody was purified using affinity purification.

Storage

-20 Celsius degree. Avoid repeated freeze/thaw cycles.

Alternative antibody names

DNA mismatch repair protein Msh2 antibody, hMSH2 antibody, MutS protein homolog 2 antibody

Database links

Human UniProt/Swiss-Prot:P43246;Mouse UniPort/Swiss-Prot: P43247;Rat UniProt/Swiss-Port: P54275;Human Entrez Gene: 4436;Mouse Entrez Gene: 17685;Rat Entrez Gene: Rn.3174

Protein names

DNA mismatch repair protein Msh2 , hMSH2 , MutS protein homolog 2

Protein function

Component of the post-replicative DNA mismatch repair system (MMR). Forms two different heterodimers: MutS alpha (MSH2-MSH6 heterodimer) and MutS beta (MSH2-MSH3 heterodimer) which binds to DNA mismatches thereby initiating DNA repair. When bound, heterodimers bend the DNA helix and shields approximately 20 base pairs. MutS alpha recognizes single base mismatches and dinucleotide insertion-deletion loops (IDL) in the DNA. MutS beta recognizes larger insertion-deletion loops up to 13 nucleotides long. After mismatch binding, MutS alpha or beta forms a ternary complex with the MutL alpha heterodimer, which is thought to be responsible for directing the downstream MMR events, including strand discrimination, excision, and resynthesis. ATP binding and hydrolysis play a pivotal role in mismatch repair functions. The ATPase activity associated with MutS alpha regulates binding similar to a molecular switch: mismatched DNA provokes ADP–>ATP exchange, resulting in a discernible conformational transition that converts MutS alpha into a sliding clamp capable of hydrolysis-independent diffusion along the DNA backbone. This transition is crucial for mismatch repair. MutS alpha may also play a role in DNA homologous recombination repair. In melanocytes may modulate both UV-B-induced cell cycle regulation and apoptosis.

Protein tissue specificity

Ubiquitously expressed.

Involvement in disease

Hereditary non-polyposis colorectal cancer 1 (HNPCC1) [MIM:120435]: An autosomal dominant disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic tumors of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world. Clinically, HNPCC is often divided into two subgroups. Type I is characterized by hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II is characterized by increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term ‘suspected HNPCC’ or ‘incomplete HNPCC’ can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Muir-Torre syndrome (MRTES) [MIM:158320]: Rare autosomal dominant disorder characterized by sebaceous neoplasms and visceral malignancy. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. . Note: Disease susceptibility is associated with variations affecting the gene represented in this entry.; Mismatch repair cancer syndrome (MMRCS) [MIM:276300]: An autosomal recessive, rare, childhood cancer predisposition syndrome encompassing a broad tumor spectrum. This includes hematological malignancies, central nervous system tumors, Lynch syndrome-associated malignancies such as colorectal tumors as well as multiple intestinal polyps, embryonic tumors and rhabdomyosarcoma. Multiple cafe-au-lait macules, a feature reminiscent of neurofibromatosis type 1, are often found as first manifestation of the underlying cancer. Areas of skin hypopigmentation have also been reported in MMRCS patients. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Colorectal cancer (CRC) [MIM:114500]: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history. . Note: Disease susceptibility may be associated with variations affecting the gene represented in this entry.

Protein sequence and domain

Belongs to the DNA mismatch repair MutS family.

Protein post-translational modifications

Phosphorylated by PRKCZ, which may prevent MutS alpha degradation by the ubiquitin-proteasome pathway.

Protein cellular localization

Nucleus

Research area

All research areas>Tumor Suppressor/Apoptosis>MSH
(View all antibody categories related to Tumor Suppressor/Apoptosis)

Note

AntibodyPlus can customize MSH2 Antibody according to your requirement, including bulk product size,etc. Please contact info@antibodyplus.com. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.

Supplier

St John’s Laboratory Ltd.

Product type

Primary antibody

Reviews


There are no reviews yet.

Only logged in customers who have purchased this product may leave a review

There are no reviews for this product yet.
By submitting a review, get following benefits:

1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!

view database submit reviews

There is no extra validation for this product yet.
Check other extra validated antibodies below:



Welcome to AntibodyPlus!